Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: Int J Cancer. 2017 Sep 13;141(12):2462–2470. doi: 10.1002/ijc.31019

Table 5.

Age at attained height in relation to breast cancer incidence, stratified by age at menarche, 1999–2015.

Age at menarche ≥14 years
All invasive breast cancer (n=205)
ER+ breast cancer (n=118)
ER- breast cancer (n=60)
Person-years Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI
Age at attained height (years)
 >17 30,697 49 1.0 Ref 26 1.0 Ref 13 1.0 Ref
 13–17 84,657 156 1.15 (0.83, 1.59) 92 1.26 (0.81, 1.97) 47 1.29 (0.69, 2.41)
Age at menarche 12–13 years
All invasive breast cancer (n=609)
ER+ breast cancer (n=371)
ER- breast cancer (n=181)
Person-years Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI
Age at attained height (years)
 >17 58,808 111 1.0 Ref 69 1.0 Ref 31 1.0 Ref
 13–17 256,149 462 0.94 (0.76, 1.15) 277 0.89 (0.68, 1.16) 140 1.03 (0.70, 1.52)
 <13 14,737 36 1.21 (0.83, 1.76) 25 1.32 (0.83, 2.09) 10 1.25 (0.61, 2.56)
Age at menarche ≤11 years
All invasive breast cancer (n=347)
ER+ breast cancer (n=207)
ER- breast cancer (n=112)
Person-years Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI
Age at attained height (years)
 >17 23,012 41 1.0 Ref 27 1.0 Ref 11 1.0 Ref
 13–17 128,498 225 0.95 (0.68, 1.33) 130 0.85 (0.56, 1.29) 77 1.18 (0.63, 2.23)
 <13 33,561 81 1.23 (0.84, 1.79) 50 1.15 (0.72, 1.85) 24 1.35 (0.66, 2.78)

ER, estrogen receptor; HR, hazard ratio; CI, confidence interval Multivariable HRs are adjusted for age, questionnaire cycle, family history of breast cancer, current BMI (continuous, kg/m2), parity/age at first birth, oral contraceptive use, menopausal status, estrogen plus progestin use, education, and adult height.